

Schizophrenia

Nature Reviews Disease Primers

1, 15067

DOI: [10.1038/nrdp.2015.67](https://doi.org/10.1038/nrdp.2015.67)

Citation Report

#	ARTICLE	IF	CITATIONS
1	How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis. Trends in Cognitive Sciences, 2015, 19, 744-756.	4.0	163
2	Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. Frontiers in Pharmacology, 2016, 7, 422.	1.6	75
3	Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study. Psychological Medicine, 2016, 46, 3199-3211.	2.7	29
4	Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model. Neuroscience and Biobehavioral Reviews, 2016, 70, 260-270.	2.9	93
5	Relationship Between Objectively Measured Sedentary Behavior and Cognitive Performance in Patients With Schizophrenia Vs Controls. Schizophrenia Bulletin, 2017, 43, sbw126.	2.3	30
6	Sex-Dependent Association of Perigenual Anterior Cingulate Cortex Volume and Migration Background, an Environmental Risk Factor for Schizophrenia. Schizophrenia Bulletin, 2017, 43, sbw138.	2.3	15
7	Schizophrenia treatment: an obstacle course. Lancet Psychiatry, the, 2016, 3, 310-312.	3.7	3
8	The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica, 2017, 135, 296-309.	2.2	90
9	Differences of temporal dynamics and signal complexity of gamma band oscillations in first-episode psychosis during a working memory task. Journal of Neural Transmission, 2017, 124, 853-862.	1.4	3
10	Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 228-235.	2.5	20
11	Identification of genetic loci shared between schizophrenia and the Big Five personality traits. Scientific Reports, 2017, 7, 2222.	1.6	79
12	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. Therapeutic Advances in Psychopharmacology, 2017, 7, 1-14.	1.2	20
13	Unravelling socio-motor biomarkers in schizophrenia. NPJ Schizophrenia, 2017, 3, 8.	2.0	32
14	Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications, 2017, 8, 14774.	5.8	114
15	The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia. European Neuropsychopharmacology, 2017, 27, 180-191.	0.3	20
16	Genetic insights into the neurodevelopmental origins of schizophrenia. Nature Reviews Neuroscience, 2017, 18, 727-740.	4.9	377
17	Inferring Relevant Cell Types for Complex Traits by Using Single-Cell Gene Expression. American Journal of Human Genetics, 2017, 101, 686-699.	2.6	102
18	Studying Developmental Psychopathology Related to Psychotic Disorders—Challenges and Paradigms in Human Studies. Schizophrenia Bulletin, 2017, 43, 1169-1171.	2.3	4

#	ARTICLE	IF	CITATIONS
20	Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine. <i>Neurochemical Research</i> , 2017, 42, 3033-3040.	1.6	8
21	The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. <i>Molecular Neuropsychiatry</i> , 2017, 3, 37-52.	3.0	32
22	A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain. <i>Schizophrenia Research</i> , 2017, 187, 67-73.	1.1	18
23	Auditory prediction errors as individual biomarkers of schizophrenia. <i>NeuroImage: Clinical</i> , 2017, 15, 264-273.	1.4	37
24	Continuous assessment of schizophrenia using heart rate and accelerometer data. <i>Physiological Measurement</i> , 2017, 38, 1456-1471.	1.2	24
25	Adolescent Stress as a Driving Factor for Schizophrenia Development—A Basic Science Perspective. <i>Schizophrenia Bulletin</i> , 2017, 43, 486-489.	2.3	56
26	Putative Role of Endocannabinoids in Schizophrenia. , 2017, , 83-113.		0
27	Neuroanatomical and Symptomatic Sex Differences in Individuals at Clinical High Risk for Psychosis. <i>Frontiers in Psychiatry</i> , 2017, 8, 291.	1.3	17
28	Theranostic Biomarkers for Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 733.	1.8	78
29	Abnormally Increased Secretion in Olfactory Neuronal Precursors from a Case of Schizophrenia Is Modulated by Melatonin: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1439.	1.8	8
30	The Energy Metabolism Dysfunction in Psychiatric Disorders Postmortem Brains: Focus on Proteomic Evidence. <i>Frontiers in Neuroscience</i> , 2017, 11, 493.	1.4	108
31	Functionally Biased D2R Antagonists: Targeting the β^2 -Arrestin Pathway to Improve Antipsychotic Treatment. <i>ACS Chemical Biology</i> , 2018, 13, 1038-1047.	1.6	24
32	A review of physiological and behavioral monitoring with digital sensors for neuropsychiatric illnesses. <i>Physiological Measurement</i> , 2018, 39, 05TR01.	1.2	86
33	Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. <i>Psychiatry Research</i> , 2018, 265, 25-38.	1.7	79
34	Network Neuroscience: A Framework for Developing Biomarkers in Psychiatry. <i>Current Topics in Behavioral Neurosciences</i> , 2018, 40, 79-109.	0.8	16
35	Comprehensive pathway analyses of schizophrenia risk loci point to dysfunctional postsynaptic signaling. <i>Schizophrenia Research</i> , 2018, 199, 195-202.	1.1	26
36	Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 187-205.	2.2	59
37	Genetic Overlap Between Schizophrenia and Volumes of Hippocampus, Putamen, and Intracranial Volume Indicates Shared Molecular Genetic Mechanisms. <i>Schizophrenia Bulletin</i> , 2018, 44, 854-864.	2.3	85

#	ARTICLE	IF	CITATIONS
38	How can genetics help understand the relationship between cognitive dysfunction and schizophrenia?. <i>Scandinavian Journal of Psychology</i> , 2018, 59, 26-31.	0.8	9
39	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 555.	6.0	516
40	Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia. <i>Schizophrenia Research</i> , 2018, 201, 254-260.	1.1	12
41	Recent Progress in Pharmacogenomics of Antipsychotic Drug Response. <i>Current Psychiatry Reports</i> , 2018, 20, 24.	2.1	22
42	Polygenic Risk Scores in Clinical Psychology: Bridging Genomic Risk to Individual Differences. <i>Annual Review of Clinical Psychology</i> , 2018, 14, 119-157.	6.3	110
43	GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 733-753.	2.8	80
44	Elemental fingerprinting of schizophrenia patient blood plasma before and after treatment with antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 565-570.	1.8	15
45	Clozapine versus olanzapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	1.5	1
46	Clozapine versus quetiapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	1.5	0
47	Clozapine versus risperidone for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	1.5	0
48	Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. <i>BMC Psychiatry</i> , 2018, 18, 365.	1.1	22
49	The Role of the Eukaryotic Translation Initiation Factor 4E (eIF4E) in Neuropsychiatric Disorders. <i>Frontiers in Genetics</i> , 2018, 9, 561.	1.1	56
50	The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 303-318.	1.2	129
51	Early Senescence and Leukocyte Telomere Shortening in SCHIZOPHRENIA: A Role for Cytomegalovirus Infection?. <i>Brain Sciences</i> , 2018, 8, 188.	1.1	11
52	Schizophrenia and Exercise. , 2018, , 65-82.		0
53	Progressive Grey Matter Volume Changes in Patients with Schizophrenia over 6 Weeks of Antipsychotic Treatment and Their Relationship to Clinical Improvement. <i>Neuroscience Bulletin</i> , 2018, 34, 816-826.	1.5	22
54	Reagent Validation to Facilitate Experimental Reproducibility. <i>Current Protocols in Pharmacology</i> , 2018, 81, e40.	4.0	4
55	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , 2018, 17, 149-160.	4.8	188

#	ARTICLE	IF	CITATIONS
56	Reproducibility in Biomedical Research. , 2018, , 1-66.		1
57	Vaccinia-related kinase 2 modulates role of dysbindin by regulating protein stability. <i>Journal of Neurochemistry</i> , 2018, 147, 609-625.	2.1	6
58	Immediate Early Genes Anchor a Biological Pathway of Proteins Required for Memory Formation, Long-Term Depression and Risk for Schizophrenia. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 23.	1.0	29
59	Shorter telomere length in schizophrenia: Evidence from a real-world population and meta-analysis of most recent literature. <i>Schizophrenia Research</i> , 2018, 202, 37-45.	1.1	40
60	Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders. <i>International Journal of Biological Sciences</i> , 2018, 14, 341-357.	2.6	194
61	The novel atypical antipsychotic cariprazine demonstrates dopamine D2receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 1129-1139.	1.9	10
62	Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling. <i>PLoS ONE</i> , 2018, 13, e0196936.	1.1	3
63	Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment. <i>Medicinal Research Reviews</i> , 2019, 39, 386-403.	5.0	36
64	Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. <i>ACS Chemical Neuroscience</i> , 2019, 10, 58-78.	1.7	13
65	Decreased Cross-Domain Mutual Information in Schizophrenia From Dynamic Connectivity States. <i>Frontiers in Neuroscience</i> , 2019, 13, 873.	1.4	11
66	Gambling disorder. <i>Nature Reviews Disease Primers</i> , 2019, 5, 51.	18.1	233
67	Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. <i>Journal of Experimental Psychopathology</i> , 2019, 10, 204380871986569.	0.4	58
68	Translational research identifies a metabolism pathway involved in first-episode of schizophrenia: Towards precision medicine. <i>EBioMedicine</i> , 2019, 46, 19-20.	2.7	0
69	Suicide in Schizophrenia: An Educational Overview. <i>Medicina (Lithuania)</i> , 2019, 55, 361.	0.8	93
70	The Cavan-Monaghan First Episode Psychosis Study (CAMFEPS): arbitrary diagnostic boundaries across the gene-environment interface and within evolving models of care. <i>Irish Journal of Psychological Medicine</i> , 2019, 36, 293-303.	0.7	7
71	Genetics and genetic counseling in psychiatry: Results from an opinion survey of professionals and users. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e830.	0.6	8
72	Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode. <i>American Journal of Psychiatry</i> , 2019, 176, 811-819.	4.0	123
73	On the origin of schizophrenia: Testing evolutionary theories in the post-genomic era. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 723-730.	1.0	11

#	ARTICLE	IF	CITATIONS
74	The Possible Role of Telomere Length and Chemokines in the Aging Process: A Transdiagnostic Review in Psychiatry. <i>Current Psychiatry Research and Reviews</i> , 2019, 15, 171-192.	0.1	0
75	Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia. <i>European Psychiatry</i> , 2019, 62, 130-137.	0.1	8
76	<p>Associations Of Personality Traits With The Capacity-Performance Discrepancy Of Functional Outcome In Patients With Schizophrenia</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2869-2877.	1.0	5
77	Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. <i>BMC Psychiatry</i> , 2019, 19, 362.	1.1	35
78	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , 2019, 24, 38-69.	0.7	87
79	<p>Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation</p>. <i>Neuropsychiatric Disease and Treatment</i> . 2019. Volume 15. 2537-2550.	1.0	20
80	Emerging role of innate B1 cells in the pathophysiology of autoimmune and neuroimmune diseases: Association with inflammation, oxidative and nitrosative stress and autoimmune responses. <i>Pharmacological Research</i> , 2019, 148, 104408.	3.1	35
81	Neuroimaging and the Longitudinal Course of Schizophrenia. , 2019, , 183-218.		0
82	Stress dynamically regulates co-expression networks of glucocorticoid receptor-dependent MDD and SCZ risk genes. <i>Translational Psychiatry</i> , 2019, 9, 41.	2.4	9
83	The Shared and Distinct White Matter Networks Between Drug-Naive Patients With Obsessive-Compulsive Disorder and Schizophrenia. <i>Frontiers in Neuroscience</i> , 2019, 13, 96.	1.4	17
84	Towards artificial intelligence in mental health by improving schizophrenia prediction with multiple brain parcellation ensemble-learning. <i>NPI Schizophrenia</i> , 2019, 5, 2.	2.0	71
85	From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness. <i>Psychiatry Journal</i> , 2019, 2019, 1-15.	0.7	62
86	Treatment-Resistant Schizophrenia: Insights From Genetic Studies and Machine Learning Approaches. <i>Frontiers in Pharmacology</i> , 2019, 10, 617.	1.6	19
87	Analysis of methylation and -141C Ins/Del polymorphisms of the dopamine receptor D2 gene in patients with schizophrenia. <i>Psychiatry Research</i> , 2019, 278, 135-140.	1.7	17
88	Therapeutic Potential of Exogenous Ketone Supplement Induced Ketosis in the Treatment of Psychiatric Disorders: Review of Current Literature. <i>Frontiers in Psychiatry</i> , 2019, 10, 363.	1.3	44
89	Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia. <i>Molecular Omics</i> , 2019, 15, 173-188.	1.4	33
90	The phenolic interactome and gut microbiota: opportunities and challenges in developing applications for Schizophrenia and autism. <i>Psychopharmacology</i> , 2019, 236, 1471-1489.	1.5	8
91	<p>>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1365-1379.	1.0	28

#	ARTICLE	IF	CITATIONS
92	Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment. <i>Frontiers in Neuroscience</i> , 2019, 13, 355.	1.4	6
93	Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. <i>Science Advances</i> , 2019, 5, eaau9093.	4.7	22
94	Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. <i>World Psychiatry</i> , 2019, 18, 208-224.	4.8	93
95	Maintenance of effects after discontinuation of early intervention services for psychosis: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2019, 29, S429.	0.3	0
96	Default mode network connectivity is associated with long-term clinical outcome in patients with schizophrenia. <i>NeuroImage: Clinical</i> , 2019, 22, 101805.	1.4	22
97	P.1.13 Neuroplastic changes following chronic treatment with antipsychotic blonanserin in rats: Implications for schizophrenia. <i>European Neuropsychopharmacology</i> , 2019, 29, S642-S643.	0.3	0
98	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability. <i>Npj Parkinson's Disease</i> , 2019, 5, 6.	2.5	83
99	Pathways linking obesity to neuropsychiatric disorders. <i>Nutrition</i> , 2019, 66, 16-21.	1.1	61
100	Klotho, vitamin D and homocysteine levels during acute episode and remission periods in schizophrenia patients. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 178-184.	0.7	13
102	Epigenetic Factors in Schizophrenia: Mechanisms and Experimental Approaches. <i>Molecular Neuropsychiatry</i> , 2019, 5, 6-12.	3.0	15
103	Mapping causal pathways from genetics to neuropsychiatric disorders using genome-wide imaging genetics: Current status and future directions. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 357-369.	1.0	22
104	Mismatch negativity-indexed auditory change detection of speech sounds in early and chronic schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2019, 287, 1-9.	0.9	18
105	The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS). <i>Frontiers in Psychiatry</i> , 2018, 9, 757.	1.3	32
106	Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 240-252.	4.0	32
107	Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 271-293.	0.8	16
108	Omics in schizophrenia: current progress and future directions of antipsychotic treatments. <i>Journal of Bio-X Research</i> , 2019, 2, 145-152.	0.3	2
109	Reduction of Involuntary Admissions in Patients With Severe Psychotic Disorders Treated in the ACCESS Integrated Care Model Including Therapeutic Assertive Community Treatment. <i>Frontiers in Psychiatry</i> , 2019, 10, 736.	1.3	20
110	P.404 Neuroplastic changes following chronic treatment with antipsychotic blonanserin in rats: Implications for schizophrenia. <i>European Neuropsychopharmacology</i> , 2019, 29, S286-S287.	0.3	0

#	ARTICLE	IF	CITATIONS
111	Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019. <i>Current Psychiatry Reports</i> , 2019, 21, 124.	2.1	16
112	Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases. <i>Frontiers in Neurology</i> , 2019, 10, 1315.	1.1	46
113	The Reeler Mouse: A Translational Model of Human Neurological Conditions, or Simply a Good Tool for Better Understanding Neurodevelopment?. <i>Journal of Clinical Medicine</i> , 2019, 8, 2088.	1.0	19
115	Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2019, 45, 742-751.	2.3	172
116	Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls. <i>Schizophrenia Bulletin</i> , 2019, 45, 794-803.	2.3	24
117	Spatial dynamics within and between brain functional domains: A hierarchical approach to study time-varying brain function. <i>Human Brain Mapping</i> , 2019, 40, 1969-1986.	1.9	52
118	Differential expression of the ghrelin-related mRNAs GHS-R1a, GHS-R1b, and MBOAT4 in Japanese patients with schizophrenia. <i>Psychiatry Research</i> , 2019, 272, 334-339.	1.7	8
119	Running in the Family? Structural Brain Abnormalities and IQ in Offspring, Siblings, Parents, and Co-twins of Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 1209-1217.	2.3	15
120	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2019, 176, 21-28.	4.0	127
121	Dopamine: Functions, Signaling, and Association with Neurological Diseases. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 31-59.	1.7	537
122	Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. <i>CNS Spectrums</i> , 2019, 24, 479-495.	0.7	17
123	You're Not Hallucinating: Potential New Targets for Schizophrenia Treatment. <i>Neurosurgery</i> , 2019, 84, E146-E147.	0.6	2
124	One hundred years ago: Nijinsky and the origins of schizophrenia. <i>Brain</i> , 2019, 142, 220-226.	3.7	4
125	Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer's disease and schizophrenia: Insights from studies in patient populations and animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 112-137.	2.9	56
126	Prediction of psychosis in prodrome: development and validation of a simple, personalized risk calculator. <i>Psychological Medicine</i> , 2019, 49, 1990-1998.	2.7	59
127	The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention. <i>Schizophrenia Bulletin</i> , 2019, 45, 148-157.	2.3	109
128	Lipids as biomarkers of brain disorders. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 351-374.	5.4	53
129	Facial Emotion Recognition and Persecutory Ideation in Paranoid Schizophrenia. <i>Psychological Reports</i> , 2020, 123, 1099-1116.	0.9	9

#	ARTICLE	IF	CITATIONS
130	Dysregulated Prefrontal Cortical RhoA Signal Transduction in Bipolar Disorder with Psychosis: New Implications for Disease Pathophysiology. <i>Cerebral Cortex</i> , 2020, 30, 59-71.	1.6	3
131	Psychiatric symptoms and quality of life in older adults with schizophrenia spectrum disorder: results from a multicenter study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 673-688.	1.8	14
132	Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. <i>Molecular Psychiatry</i> , 2020, 25, 2355-2372.	4.1	22
133	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 11-22.	1.8	34
135	Trajectory of neurological examination abnormalities in antipsychotic-naïve first-episode psychosis population: a 1 year follow-up study. <i>Psychological Medicine</i> , 2020, 50, 2057-2065.	2.7	5
136	The pathophysiological impact of stress on the dopamine system is dependent on the state of the critical period of vulnerability. <i>Molecular Psychiatry</i> , 2020, 25, 3278-3291.	4.1	49
137	Neural correlates of theory of mind and empathy in schizophrenia: An activation likelihood estimation meta-analysis. <i>Journal of Psychiatric Research</i> , 2020, 120, 163-174.	1.5	36
138	Schizophrenia, recovery and the self: An introduction to the special issue on metacognition. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100167.	0.7	7
139	Effects of an adenosine A2A agonist on the rewarding associative properties of nicotine and neural plasticity in a rodent model of schizophrenia. <i>Journal of Psychopharmacology</i> , 2020, 34, 137-144.	2.0	11
140	Deep brain stimulation in treatment resistant schizophrenia: A pilot randomized cross-over clinical trial. <i>EBioMedicine</i> , 2020, 51, 102568.	2.7	50
141	High risk genotypes for schizophrenia may have been adaptive in the context of smallpox. <i>Medical Hypotheses</i> , 2020, 137, 109556.	0.8	0
142	Polypharmacy in schizophrenia. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 183-192.	1.2	43
143	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 349.	6.0	226
144	Relationship between resting-state theta phase-gamma amplitude coupling and neurocognitive functioning in patients with first-episode psychosis. <i>Schizophrenia Research</i> , 2020, 216, 154-160.	1.1	14
145	Genomic Basis of Psychiatric Illnesses and Response to Psychiatric Drug Treatment Modalities. , 2020, , 73-110.		0
146	Multiple rare inherited variants in a four generation schizophrenia family offer leads for complex mode of disease inheritance. <i>Schizophrenia Research</i> , 2020, 216, 288-294.	1.1	10
147	Twin studies of brain structure and cognition in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 109, 103-113.	2.9	10
148	Language-Related Neurophysiological Deficits in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2020, 51, 222-233.	0.9	16

#	ARTICLE	IF	CITATIONS
149	Profiling of schizophrenia-associated serum peptides by MALDI-TOF-MS. <i>Journal of Neural Transmission</i> , 2020, 127, 95-101.	1.4	2
150	Dopamine-Induced Dysconnectivity Between Salience Network and Auditory Cortex in Subjects With Psychotic-like Experiences: A Randomized Double-Blind Placebo-Controlled Study. <i>Schizophrenia Bulletin</i> , 2020, 46, 732-740.	2.3	10
151	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	3
152	Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. <i>Annals of General Psychiatry</i> , 2020, 19, 55.	1.2	30
153	Thyroid function assessment before and after diagnosis of schizophrenia: A community-based study. <i>Psychiatry Research</i> , 2020, 293, 113356.	1.7	13
154	Special Article: Translational Science Update. Pharmacological Implications of Emerging Schizophrenia Genetics. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 323-329.	0.7	10
155	Efficacy and safety of once-monthly Risperidone ISMÂ® in schizophrenic patients with an acute exacerbation. <i>NPJ Schizophrenia</i> , 2020, 6, 37.	2.0	15
156	Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis. <i>JAMA Network Open</i> , 2020, 3, e2024335.	2.8	19
157	Genome-wide DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia in the Chinese Han population. <i>Molecular Psychiatry</i> , 2021, 26, 4475-4485.	4.1	24
158	Mindfulness-Based Interventions for In-Patients With Schizophrenia Spectrum Disordersâ€”A Qualitative Approach. <i>Frontiers in Psychiatry</i> , 2020, 11, 600.	1.3	20
159	Ubiquitinâ€™proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia. <i>Scientific Reports</i> , 2020, 10, 12655.	1.6	14
160	Acute psychiatric illness and drug addiction during pregnancy and the puerperium. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 172, 125-144.	1.0	2
161	Deficits and compensation: Attentional control cortical networks in schizophrenia. <i>NeuroImage: Clinical</i> , 2020, 27, 102348.	1.4	17
162	<p>Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study</p>. <i>Integrated Pharmacy Research & Practice</i> , 2020, Volume 9, 205-217.	0.9	3
163	Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. <i>Frontiers in Public Health</i> , 2020, 8, 391.	1.3	1
164	Neurodevelopmental predictors of conversion to schizophrenia and other psychotic disorders in adolescence and young adulthood in clinical high risk individuals. <i>Schizophrenia Research</i> , 2020, 224, 170-172.	1.1	7
165	Are CB2 Receptors a New Target for Schizophrenia Treatment?. <i>Frontiers in Psychiatry</i> , 2020, 11, 587154.	1.3	17
166	Impact cÃ©rÃ©bral structurel et fonctionnel de la Clozapine chez les patients souffrant de schizophrÃ©nie: revue systÃ©matique des Ã©tudes longitudinales en neuroimagerie: Structural and functional impact of clozapine in patients with schizophrenia: systematic review of neuroimaging longitudinal studies. <i>Canadian Journal of Psychiatry</i> , 2020, 66, 070674372096645.	0.9	0

#	ARTICLE	IF	CITATIONS
167	SNX29, a new susceptibility gene shared with major mental disorders in Han Chinese population. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 526-534.	1.3	10
168	A comprehensive model of predictors of quality of life in older adults with schizophrenia: results from the CSA study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 1411-1425.	1.6	9
169	Perturbations in the catecholamine metabolism and protective effect of α 3-(3, 4-dimethoxy) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 66 and <i>in silico</i> studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 3523-3532.	2.0	7
170	Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research. <i>Molecular Psychiatry</i> , 2020, 25, 3129-3139.	4.1	46
171	Microbiome and Schizophrenia: Current Evidence and Future Challenges. <i>Current Behavioral Neuroscience Reports</i> , 2020, 7, 51-61.	0.6	9
172	Different serum protein factor levels in first-episode drug-naïve patients with schizophrenia characterized by positive and negative symptoms. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 472-479.	1.0	15
173	Risk of obstructive sleep apnea in patients with schizophrenia: a nationwide population-based cohort study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 1671-1677.	1.6	4
174	Drug repositioning for psychiatric and neurological disorders through a network medicine approach. <i>Translational Psychiatry</i> , 2020, 10, 141.	2.4	24
175	The 12-year trend report of antipsychotic usage in a nationwide claims database derived from four million people in Japan. <i>Journal of Psychiatric Research</i> , 2020, 127, 28-34.	1.5	9
176	Early magnetic resonance imaging biomarkers of schizophrenia spectrum disorders: Toward a fetal imaging perspective. <i>Development and Psychopathology</i> , 2020, 33, 1-15.	1.4	1
177	Causes of death in clozapine-treated patients in a catchment area: a 10-year retrospective case-control study. <i>European Neuropsychopharmacology</i> , 2020, 36, 160-166.	0.3	5
178	The association between exposure to herpes simplex virus type 1 (HSV-1) and cognitive functioning in schizophrenia: A meta-analysis. <i>Psychiatry Research</i> , 2020, 291, 113157.	1.7	9
179	Long-term outcome predictors after functional remediation in patients with bipolar disorder. <i>Psychological Medicine</i> , 2022, 52, 314-322.	2.7	5
180	Are Circadian Disturbances a Core Pathophysiological Component of Schizophrenia?. <i>Journal of Biological Rhythms</i> , 2020, 35, 325-339.	1.4	25
181	Lack of Helios During Neural Development Induces Adult Schizophrenia-Like Behaviors Associated With Aberrant Levels of the TRIF-Recruiter Protein WDFY1. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 93.	1.8	6
182	Understanding Cortical Dysfunction in Schizophrenia With TMS/EEG. <i>Frontiers in Neuroscience</i> , 2020, 14, 554.	1.4	10
184	Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 201-207.	1.2	13
185	Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2021, 42, 272-278.	1.1	5

#	ARTICLE	IF	CITATIONS
186	Sesgo de muestreo y sus implicaciones en la evaluación a personas con riesgo genético de padecer esquizofrenia. <i>Psiquiatría Biológica</i> , 2020, 27, 34-39.	0.0	0
187	<p></p>The Effectiveness of a Mindfulness-Based Psychoeducation Programme for Emotional Regulation in Individuals with Schizophrenia Spectrum Disorders: A Pilot Randomised Controlled Trial</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 729-747.	1.0	18
188	On the Origins of Schizophrenia. <i>American Journal of Psychiatry</i> , 2020, 177, 291-297.	4.0	40
189	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 562-586.	0.7	13
190	A simple mechanistic terminology of psychoactive drugs: a proposal. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1331-1339.	1.4	17
191	The involvement of neuronal chloride transporter deficiencies in epilepsy. , 2020, , 329-366.		3
192	In the Loop: Extrastriatal Regulation of Spiny Projection Neurons by GPR52. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2066-2076.	1.7	5
193	Diffusion-weighted MRI in neurodegenerative and psychiatric animal models: Experimental strategies and main outcomes. <i>Journal of Neuroscience Methods</i> , 2020, 343, 108814.	1.3	3
194	A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis. <i>Schizophrenia Research</i> , 2022, 249, 56-62.	1.1	10
195	Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms. <i>Lipids in Health and Disease</i> , 2020, 19, 159.	1.2	38
196	Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 463-472.	0.9	4
197	<p></p>The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 191-199.	1.0	16
198	Stem Cells for Improving the Treatment of Neurodevelopmental Disorders. <i>Stem Cells and Development</i> , 2020, 29, 1118-1130.	1.1	7
199	Neuroprotective role of taurine on MK-801-induced memory impairment and hyperlocomotion in zebrafish. <i>Neurochemistry International</i> , 2020, 135, 104710.	1.9	19
200	The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index. <i>BMC Psychiatry</i> , 2020, 20, 77.	1.1	14
201	Effects of Cannabis Use on the Protein and Lipid Profile of Olfactory Neuroepithelium Cells from Schizophrenia Patients Studied by Synchrotron-Based FTIR Spectroscopy. <i>Biomolecules</i> , 2020, 10, 329.	1.8	5
202	Two Novel Loci of RELN Associated With Antipsychotics Response in Chinese Han Population. <i>Frontiers in Pharmacology</i> , 2020, 11, 7.	1.6	4
203	<p></p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 519-534.	1.0	339

#	ARTICLE	IF	CITATIONS
204	Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring. <i>Scientific Reports</i> , 2020, 10, 1219.	1.6	2
205	Face pareidolia in schizophrenia. <i>Schizophrenia Research</i> , 2020, 218, 138-145.	1.1	16
206	Autism spectrum disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 5.	18.1	746
207	Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. <i>PLoS Biology</i> , 2020, 18, e3000604.	2.6	98
208	Transcriptome analysis of fibroblasts from schizophrenia patients reveals differential expression of schizophrenia-related genes. <i>Scientific Reports</i> , 2020, 10, 630.	1.6	22
209	An investigation of retinal layer thicknesses in unaffected first-degree relatives of schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 218, 255-261.	1.1	17
210	Staging and profiling for schizophrenia spectrum disorders: Inter-rater reliability after a short training course. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109856.	2.5	3
211	Mitochondrial Dysfunction in Schizophrenia. <i>BioEssays</i> , 2020, 42, e1900202.	1.2	28
212	Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 379.	1.3	37
213	Conversion to psychosis in adolescents and adults: similar proportions, different predictors. <i>Psychological Medicine</i> , 2021, 51, 2003-2011.	2.7	14
214	Maternal Immune Activation by Poly I:C as a preclinical Model for Neurodevelopmental Disorders: A focus on Autism and Schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 113, 546-567.	2.9	108
215	The role of the gut microbiome in the development of schizophrenia. <i>Schizophrenia Research</i> , 2021, 234, 4-23.	1.1	60
216	Effects of risperidone on blood levels of interleukin-6 in schizophrenia. <i>Medicine (United States)</i> , 2020, 99, e19694.	0.4	10
217	Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. , 2020, 213, 107554.		83
218	Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence. <i>BMJ Open</i> , 2020, 10, e035073.	0.8	3
219	Cigarette smoking and schizophrenia: Mendelian randomisation study. <i>British Journal of Psychiatry</i> , 2021, 218, 98-103.	1.7	6
220	Do rat auditory event related potentials exhibit human mismatch negativity attributes related to predictive coding?. <i>Hearing Research</i> , 2021, 399, 107992.	0.9	7
221	Exploration of symptom dimensions and duration of untreated psychosis within a staging model of schizophrenia spectrum disorders. <i>Microbial Biotechnology</i> , 2021, 15, 669-675.	0.9	9

#	ARTICLE	IF	CITATIONS
222	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 673-682.	2.0	15
223	Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia. <i>Neuropsychopharmacology</i> , 2021, 46, 665-672.	2.8	24
224	Treating disorders across the lifespan by modulating cholinergic signaling with galantamine. <i>Journal of Neurochemistry</i> , 2021, 158, 1359-1380.	2.1	26
225	Endogenous antagonists of N-methyl-D-aspartate receptor in schizophrenia. <i>Alzheimer's and Dementia</i> , 2021, 17, 888-905.	0.4	13
226	Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?. <i>Frontiers in Pharmacology</i> , 2020, 11, 635763.	1.6	9
227	The bumpy road to achieve reliability of clinical profile characteristics in psychosis and related disorders. <i>International Journal of Methods in Psychiatric Research</i> , 2021, 30, e1858.	1.1	0
228	Mesolimbic dopamine dysregulation as a signature of information processing deficits imposed by prenatal THC exposure. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110128.	2.5	20
229	Stress impacts corticoamygdalar connectivity in an age-dependent manner. <i>Neuropsychopharmacology</i> , 2021, 46, 731-740.	2.8	11
230	Association Between REELIN Gene Polymorphisms (rs7341475 and rs262355) and Risk of Schizophrenia: an Updated Meta-analysis. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 675-690.	1.1	10
231	Microglial contribution to synaptic uptake in the prefrontal cortex in schizophrenia. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 346-351.	1.8	7
232	Multi-targeted drug design strategies for the treatment of schizophrenia. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 101-114.	2.5	10
233	Introduction: Diagnosing Comorbidity Trees in the Forest of Psychosis. , 2021, , 1-11.		0
235	Evaluation of the relationship between VRK2 , rs4380187 polymorphisms, and genetic susceptibility to schizophrenia in the Chinese Han population. <i>Journal of Gene Medicine</i> , 2021, 23, e3313.	1.4	0
236	There are no "side-effects", just "core-effects" of antipsychotic pharmacotherapy. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 99-100.	2.2	0
237	Identification of Risk Factors to Predict the Occurrences of Relapses in Individuals with Schizophrenia Spectrum Disorder in Iran. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 546.	1.2	5
238	Building the brain from scratch: Engineering region-specific brain organoids from human stem cells to study neural development and disease. <i>Current Topics in Developmental Biology</i> , 2021, 142, 477-530.	1.0	15
239	First-Episode & Early Psychosis in Transition-Age Youth. , 2021, , 277-310.		0
240	Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics. <i>RSC Advances</i> , 2021, 11, 16931-16941.	1.7	6

#	ARTICLE	IF	CITATIONS
241	DIA-MSE to Study Microglial Function in. <i>Methods in Molecular Biology</i> , 2021, 2228, 341-352.	0.4	0
242	Psychotic-Like Experiences in Adolescence Occurring in Combination or Isolation: Associations with Schizophrenia Risk Factors. <i>Psychiatric Research and Clinical Practice</i> , 2021, 3, 67-75.	1.3	3
243	Brain targeting efficiency of intranasal clozapine-loaded mixed micelles following radio labeling with Technetium-99m. <i>Drug Delivery</i> , 2021, 28, 1524-1538.	2.5	21
244	Induced pluripotent stem cells for modeling schizophrenia pathogenesis. , 2021, , 105-127.		0
245	Frontal Cortex. , 2021, , 27-61.		0
246	Alternatives to Pharmacological and Psychotherapeutic Treatments in Psychiatric Disorders. <i>Psychiatry International</i> , 2021, 2, 1-24.	0.5	2
247	Menstrual Dysfunction in Women With Schizophrenia During Risperidone Maintenance Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 135-139.	0.7	2
248	Safety and tolerability of lumateperone 42Âmg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 198-205.	1.1	16
249	Increased random exploration in schizophrenia is associated with inflammation. <i>NPJ Schizophrenia</i> , 2021, 7, 6.	2.0	19
250	The neurochemistry of social reward during development: What have we learned from rodent models?. <i>Journal of Neurochemistry</i> , 2021, 157, 1408-1435.	2.1	17
252	Functional patient-derived cellular models for neuropsychiatric drug discovery. <i>Translational Psychiatry</i> , 2021, 11, 128.	2.4	7
253	Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2021, 37, 665-674.	0.9	14
254	The Value of Serum Cell-Free DNA Levels in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 637789.	1.3	7
255	Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 538-549.	2.7	17
257	Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse. <i>Clinical Therapeutics</i> , 2021, 43, 535-548.	1.1	6
258	Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder—An evidence from mouse model. <i>Brain and Behavior</i> , 2021, 11, e02113.	1.0	2
259	Advances in Proteomics Allow Insights Into Neuronal Proteomes. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 647451.	1.4	8
260	Multi-spatial-scale dynamic interactions between functional sources reveal sex-specific changes in schizophrenia. <i>Network Neuroscience</i> , 2022, 6, 357-381.	1.4	29

#	ARTICLE	IF	CITATIONS
261	Heterogeneous trajectories in schizophrenia: insights from neurodevelopment and neuroprogression models. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 74-80.	0.9	7
262	Perinatal Dietary Polyunsaturated Fatty Acids in Brain Development, Role in Neurodevelopmental Disorders. <i>Nutrients</i> , 2021, 13, 1185.	1.7	52
263	A Critical Systematic Review of Current Evidence on the Effects of Physical Exercise on Whole/Regional Grey Matter Brain Volume in Populations at Risk of Neurodegeneration. <i>Sports Medicine</i> , 2021, 51, 1651-1671.	3.1	24
264	Design of Multi-Shell Hollow Cr ₂ O ₃ Spheres for Metabolic Fingerprinting. <i>Angewandte Chemie</i> , 2021, 133, 12612-12620.	1.6	5
265	Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4467.	1.8	27
266	Biomaterials for Drugs Nose-to-Brain Transport: A New Therapeutic Approach for Neurological Diseases. <i>Materials</i> , 2021, 14, 1802.	1.3	16
267	Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study. <i>Annals of General Psychiatry</i> , 2021, 20, 27.	1.2	7
268	Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 33-45.	1.3	19
269	Current and emerging long-acting antipsychotics for the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 771-790.	1.0	19
270	Genome-wide association study of antipsychotic-induced sinus bradycardia in Chinese schizophrenia patients. <i>PLoS ONE</i> , 2021, 16, e0249997.	1.1	3
271	Evaluación de las experiencias de tipo psicótico en adolescentes españoles: Baremación del Prodromal Questionnaire-Brief (PQ-B). <i>Revista De Psicopatología Y Psicología Clínica</i> , 2021, 26, 35.	0.1	0
273	Zbtb16 regulates social cognitive behaviors and neocortical development. <i>Translational Psychiatry</i> , 2021, 11, 242.	2.4	29
274	Design of Multi-Shell Hollow Cr ₂ O ₃ Spheres for Metabolic Fingerprinting. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 12504-12512.	7.2	53
275	Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia. <i>Schizophrenia Research</i> , 2021, 231, 179-188.	1.1	6
276	TPN672: A Novel Serotonin-Dopamine Receptor Modulator for the Treatment of Schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 20-30.	1.3	3
277	Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia. <i>Pharmacological Reports</i> , 2021, 73, 1063-1078.	1.5	5
278	Changes of Hypocretin (Orexin) System in Schizophrenia: From Plasma to Brain. <i>Schizophrenia Bulletin</i> , 2021, 47, 1310-1319.	2.3	12
279	miR-936 is Increased in Schizophrenia and Inhibits Neural Development and AMPA Receptor-Mediated Synaptic Transmission. <i>Schizophrenia Bulletin</i> , 2021, 47, 1795-1805.	2.3	6

#	ARTICLE	IF	CITATIONS
280	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-“post studies. <i>Lancet Psychiatry</i> , 2021, 8, 387-404.	3.7	160
281	Assessing olfactory, memory, social and circadian phenotypes associated with schizophrenia in a genetic model based on Rim. <i>Translational Psychiatry</i> , 2021, 11, 292.	2.4	5
282	The Many Faces of Negative Symptoms in Schizophrenia. , 0, , .		2
283	Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 510.	6.0	63
284	Akt-mTOR hypoactivity in bipolar disorder gives rise to cognitive impairments associated with altered neuronal structure and function. <i>Neuron</i> , 2021, 109, 1479-1496.e6.	3.8	37
285	Abnormal Function in Dentate Nuclei Precedes the Onset of Psychosis: A Resting-State fMRI Study in High-Risk Individuals. <i>Schizophrenia Bulletin</i> , 2021, 47, 1421-1430.	2.3	12
286	Stigma toward individuals with mental disorders among Brazilian psychiatrists: a latent class analysis. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 262-268.	0.9	5
287	Particulate matter pollution associated with schizophrenia hospital re-admissions: a time-series study in a coastal Chinese city. <i>Environmental Science and Pollution Research</i> , 2021, 28, 58355-58363.	2.7	13
288	Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. <i>Journal of Psychiatric Research</i> , 2021, 138, 444-452.	1.5	11
289	Towards Clinically Relevant Oculomotor Biomarkers in Early Schizophrenia. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 688683.	1.0	5
290	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	0.9	6
291	Patients with schizophrenia have decreased COVID-19 prevalence among hospitalised patients with psychiatric and neurological diseases: A retrospective analysis in Mexican population. <i>International Journal of Clinical Practice</i> , 2021, 75, e14528.	0.8	6
292	Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. <i>Health Psychology Research</i> , 2021, 9, 24932.	0.6	5
293	Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study. <i>Translational Psychiatry</i> , 2021, 11, 343.	2.4	5
294	Brain-immune interactions in neuropsychiatric disorders: Lessons from transcriptome studies for molecular targeting. <i>Biochemical Pharmacology</i> , 2021, 188, 114532.	2.0	12
295	14-3-3 proteins at the crossroads of neurodevelopment and schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 14-32.	1.3	4
296	Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia. <i>Scientific Reports</i> , 2021, 11, 13509.	1.6	4
297	Striatal functional connectivity in psychosis relapse: A hypothesis generating study. <i>Schizophrenia Research</i> , 2022, 243, 342-348.	1.1	9

#	ARTICLE	IF	CITATIONS
298	Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea. <i>Nutrients</i> , 2021, 13, 2033.	1.7	5
299	Efficacy of Facial Exercises in Facial Expression Categorization in Schizophrenia. <i>Brain Sciences</i> , 2021, 11, 825.	1.1	4
300	Features of Inflammatory Response in Juvenile Depression with Attenuated Symptoms of Schizophrenic Spectrum. <i>Psychiatry</i> , 2021, 19, 29-38.	0.2	1
301	Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. <i>Drugs</i> , 2021, 81, 1273-1284.	4.9	41
302	Cariprazine: Patients with Treatment-Resistant Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2327-2332.	1.0	14
304	Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2141-2150.	1.0	4
305	Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. <i>International Journal of General Medicine</i> , 2021, Volume 14, 4081-4094.	0.8	4
306	Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19. <i>General Hospital Psychiatry</i> , 2021, 71, 137-139.	1.2	9
307	Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging. <i>Schizophrenia Research</i> , 2021, , .	1.1	4
308	Associations Between Genotype and Peripheral Complement Proteins in First-Episode Psychosis: Evidences From C3 and C4. <i>Frontiers in Genetics</i> , 2021, 12, 647246.	1.1	5
309	Hidden Role of Gut Microbiome Dysbiosis in Schizophrenia: Antipsychotics or Psychobiotics as Therapeutics?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7671.	1.8	37
310	Language disorder as a marker for schizophrenia. <i>Asia-Pacific Psychiatry</i> , 2022, 14, e12485.	1.2	5
311	Functioning and Happiness in People with Schizophrenia: Analyzing the Role of Cognitive Impairment. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7706.	1.2	6
312	Oxidative Stress in the Early Stage of Psychosis. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 1457-1470.	1.0	6
313	Study Protocol: The Evaluation Study for Social Cognition Measures in Japan (ESCoM). <i>Journal of Personalized Medicine</i> , 2021, 11, 667.	1.1	5
314	The 10-year trajectories of auditory hallucinations among 496 patients with a first schizophrenia-spectrum disorder: Findings from the OPUS cohort. <i>Schizophrenia Research</i> , 2021, , .	1.1	3
315	<i>Spirulina platensis</i> reduces the schizophrenic-like symptoms in rat model by restoring altered APO-E and RTN-4 protein expression in prefrontal cortex. <i>Life Sciences</i> , 2021, 277, 119417.	2.0	9
316	Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries. <i>Current Medical Research and Opinion</i> , 2021, 37, 1811-1819.	0.9	15

#	ARTICLE	IF	CITATIONS
317	Mini-review: Brain energy metabolism and its role in animal models of depression, bipolar disorder, schizophrenia and autism. <i>Neuroscience Letters</i> , 2021, 760, 136003.	1.0	15
318	Investigating the association between common DRD2/ANKK1 genetic polymorphisms and schizophrenia: a meta-analysis. <i>Journal of Genetics</i> , 2021, 100, 1.	0.4	6
320	Mindfulness-based intervention improves residual negative symptoms and cognitive impairment in schizophrenia: a randomized controlled follow-up study. <i>Psychological Medicine</i> , 2023, 53, 1390-1399.	2.7	8
322	Lower circulating neuron-specific enolase concentrations in adults and adolescents with severe mental illness. <i>Psychological Medicine</i> , 2023, 53, 1479-1488.	2.7	6
323	Current and Future Trends in Hospital Utilization of Patients With Schizophrenia in Korea: A Time Series Analysis Using National Health Insurance Data. <i>Psychiatry Investigation</i> , 2021, 18, 795-800.	0.7	7
324	An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2885-2904.	1.0	9
325	Epigenetics of Schizophrenia. <i>Psychiatry Research</i> , 2021, 305, 114218.	1.7	32
326	Comparative Study on the Functional Connectivity of Amygdala and Hippocampal Neural Circuits in Patients With First-Episode Schizophrenia and Other High-Risk Populations. <i>Frontiers in Psychiatry</i> , 2021, 12, 627198.	1.3	4
327	Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study. <i>Schizophrenia Research</i> , 2021, 235, 29-35.	1.1	12
328	Characterization of six CaMKII α variants found in patients with schizophrenia. <i>IScience</i> , 2021, 24, 103184.	1.9	10
329	Non-linear associations between retinal nerve fibre layer (RNFL) and positive and negative symptoms among men with acute and chronic schizophrenia spectrum disorder. <i>Journal of Psychiatric Research</i> , 2021, 141, 81-91.	1.5	11
330	Bacterial Translocation Associates With Aggression in Schizophrenia Inpatients. <i>Frontiers in Systems Neuroscience</i> , 2021, 15, 704069.	1.2	9
331	Neural correlates of emotional processing in psychosis risk and onset – A systematic review and meta-analysis of fMRI studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 780-788.	2.9	15
332	Shared decision making in a semi-secluded chronic psychiatric ward: The reflective lifeworld experiences of patients with schizophrenia or schizoaffective disorders and nursing staff. <i>Archives of Psychiatric Nursing</i> , 2021, 35, 519-525.	0.7	5
333	TMS-EEG: An emerging tool to study the neurophysiologic biomarkers of psychiatric disorders. <i>Neuropharmacology</i> , 2021, 197, 108574.	2.0	31
334	An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 130, 33-60.	2.9	22
335	Clinical features and psychiatric comorbidities in military veterans with schizophrenia with or without suicidality. <i>Journal of Psychiatric Research</i> , 2021, 143, 262-267.	1.5	3
336	Taurine prevents MK-801-induced shoal dispersion and altered cortisol responses in zebrafish. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110399.	2.5	8

#	ARTICLE	IF	CITATIONS
337	Target selection for deep brain stimulation in treatment resistant schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 112, 110436.	2.5	11
338	Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs, 2021, 35, 39-59.	2.7	67
340	Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. Advances in Neurobiology, 2020, 25, 155-206.	1.3	11
341	Impact of Service Organisation on Teaching and Training. , 2018, , 211-237.		4
342	The behavioral and neurochemical characterization of a Drosophila dysbindin mutant supports the contribution of serotonin to schizophrenia negative symptoms. Neurochemistry International, 2020, 138, 104753.	1.9	8
348	Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe de <i>Garcinia mangostana</i> Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placebo. Canadian Journal of Psychiatry, 2021, 66, 354-366.	0.9	3
349	The impact of a short-term cohousing initiative among schizophrenia patients, high school students, and their social context: A qualitative case study. PLoS ONE, 2018, 13, e0190895.	1.1	3
351	Incongruent Expression of Brain-Derived Neurotrophic Factor and Cortisol in Schizophrenia: Results from a Randomized Controlled Trial of Laughter Intervention. Psychiatry Investigation, 2020, 17, 1191-1199.	0.7	3
352	Effect of Cuscuta epithimum Acquainted with Risperidone on the Improvement of Clinical Symptoms and Cognitive Impairment in Patients with Schizophrenia: A Triple-Blind Randomized Placebo-Controlled Trial. , 2019, 8, e1334.		5
353	Use of the epigenetic toolbox to contextualize common variants associated with schizophrenia risk. Dialogues in Clinical Neuroscience, 2019, 21, 407-416.	1.8	3
354	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. Journal of Clinical Medicine, 2021, 10, 73.	1.0	14
355	VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. Brain Communications, 2021, 3, fcab261.	1.5	35
358	Antipsychotic utilisation and persistence in Australia: A nationwide 5-year study. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1155-1163.	1.3	6
359	Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy. Expert Review of Neurotherapeutics, 2021, 21, 1441-1453.	1.4	5
360	Disorganization of Oscillatory Activity in Animal Models of Schizophrenia. Frontiers in Neural Circuits, 2021, 15, 741767.	1.4	6
361	Salivary Metabolomics Reveals that Metabolic Alterations Precede the Onset of Schizophrenia. Journal of Proteome Research, 2021, 20, 5010-5023.	1.8	9
362	Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study. BMC Psychiatry, 2021, 21, 507.	1.1	4
363	Mindfulness-based psychoeducation for schizophrenia spectrum disorders: a qualitative analysis of participants' experiences. Contemporary Nurse, 2021, 57, 387-406.	0.4	1

#	ARTICLE	IF	CITATIONS
364	Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. Journal of Psychiatric Research, 2021, 144, 255-261.	1.5	3
365	Schizotypy. , 2016, , 1-17.		0
366	Psychotic-Like Experiences. , 2016, , 1-18.		0
367	Studying Microarray Gene Expression Data of Schizophrenic Patients for Derivation of a Diagnostic Signature through the Aid of Machine Learning. Biometrics & Biostatistics International Journal, 2016, 4, .	0.2	1
369	Psychotic-Like Experiences. , 2018, , 2950-2967.		0
370	Schizotypy. , 2018, , 3238-3254.		0
371	Difficulties in functional recovery in schizophrenia: negative and cognitive symptoms. Psihiatru Ro, 2018, 3, 30.	0.0	0
373	Epid�miologie des troubles psychotiques en milieu sp�cifique : lâ™exemple du milieu p�nitentiaire.. French Journal of Psychiatry, 2018, 1, S35.	0.1	0
374	Single-nucleotide polymorphism of CTLA-4 (rs5742909) in correlation with schizophrenia risk factor. Journal of Pharmacy and Bioallied Sciences, 2019, 11, 605.	0.2	2
375	Psychotische Erkrankungen (�Schizophrenie�). , 2020, , 275-296.		0
376	Introduction �la�classification des�psychoses endog�nes de�Karl�Leonhard. , 2020, , 1-77.		0
378	The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts. Pharmacotherapy in Psychiatry and Neurology, 2020, 36, 107-115.	0.1	0
380	Validade e Confiabilidade da Vers�o Portuguesa da Brief Motor Scale em Pessoas com Esquizofrenia: Um Estudo Preliminar. , 2020, 6, 109-117.	0.1	1
381	Hacking into Cybertherapy: Considering a Gesture-enhanced Therapy with Avatars (^{g+T}A). Kairos: Journal of Philosophy & Science, 2020, 23, 32-87.	0.2	2
382	Prediction of schizophrenia using MAOA-uVNTR polymorphism: A case�control study. Indian Journal of Psychiatry, 2020, 62, 80.	0.4	5
383	Metabolic Pathways Underlying Neuropsychiatric Disorders and Obesity. , 2020, , 415-426.		0
386	Evaluating the efficacy and safety of electro-acupuncture in patients with antipsychotic-related constipation: protocol for a randomized controlled trial. Trials, 2021, 22, 771.	0.7	0
388	Antipsychotic Medication in Schizophrenic Patients is Associated with Higher Risks of Developing Bone Fractures and Refractures. Clinical Psychopharmacology and Neuroscience, 2020, 18, 562-570.	0.9	2

#	ARTICLE	IF	CITATIONS
391	Investigating aberrantly expressed microRNAs in peripheral blood mononuclear cells from patients with treatment-resistant schizophrenia using miRNA sequencing and integrated bioinformatics. <i>Molecular Medicine Reports</i> , 2020, 22, 4340-4350.	1.1	5
393	Structural brain correlates of cognitive function in schizophrenia: A meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 37-49.	2.9	33
394	Long-term efficacy and safety of once-monthly Risperidone ISM [®] in the treatment of schizophrenia: Results from a 12-month open-label extension study. <i>Schizophrenia Research</i> , 2022, 239, 83-91.	1.1	5
395	4-Methoxycinnamic acid attenuates schizophrenia-like behaviors induced by MK-801 in mice. <i>Journal of Ethnopharmacology</i> , 2022, 285, 114864.	2.0	12
396	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 1295-1305.	1.3	10
397	Short-term functional outcome in psychotic patients: results of the Turku early psychosis study (TEPS). <i>BMC Psychiatry</i> , 2021, 21, 602.	1.1	4
398	Neuropsychiatric disorders: An immunological perspective. <i>Advances in Immunology</i> , 2021, 152, 83-155.	1.1	10
399	Glial Cell Abnormalities in Major Psychiatric Diseases: A Systematic Review of Postmortem Brain Studies. <i>Molecular Neurobiology</i> , 2022, 59, 1665-1692.	1.9	12
400	Therapeutic use of virtual reality relaxation in schizophrenia: A pilot study. <i>Psychiatry Research</i> , 2022, 309, 114389.	1.7	4
401	Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2022, Publish Ahead of Print, .	0.7	2
402	Long-term care utilization within older adults with schizophrenia: Associated factors in a multicenter study. <i>Psychiatry Research</i> , 2022, 308, 114339.	1.7	6
403	Beyond a blunted ERN - Biobehavioral correlates of performance monitoring in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 133, 104504.	2.9	9
404	Dynamic patterns within the default mode network in schizophrenia subgroups. , 2021, 2021, 1640-1643.		6
406	Prevalence and clinical characteristics of COVID-19 in inpatients with schizophrenia in Wuhan, China. <i>World Journal of Psychiatry</i> , 2022, 12, 140-150.	1.3	3
407	Transcranial Electrical Stimulation for Psychiatric Disorders in Adults: A Primer. <i>Focus (American J Psychiatry)</i> , 2022, 178, 1050-1059.	0.4	2
408	Serotonin transporter functional polymorphisms potentially increase risk of schizophrenia separately and as a haplotype. <i>Scientific Reports</i> , 2022, 12, 1336.	1.6	6
409	The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia. <i>Current Issues in Molecular Biology</i> , 2022, 44, 336-349.	1.0	8
410	Glial changes in schizophrenia: Genetic and epigenetic approach. <i>Indian Journal of Psychiatry</i> , 2022, 64, 3.	0.4	2

#	ARTICLE	IF	CITATIONS
411	Alterations of dynamic functional connectivity between visual and executive-control networks in schizophrenia. <i>Brain Imaging and Behavior</i> , 2022, 16, 1294-1302.	1.1	4
412	Functional variant rs2270363 on 16p13.3 confers schizophrenia risk by regulating <i>NMRAL1</i> . <i>Brain</i> , 2022, 145, 2569-2585.	3.7	4
413	Role of deep brain stimulation in management of psychiatric disorders. <i>Progress in Brain Research</i> , 2022, 270, 61-96.	0.9	1
414	In memory of Professor Iain Wilkinson: cognitive and neuroimaging endophenotypes in a consanguineous schizophrenia multiplex family. <i>Psychological Medicine</i> , 2022, , 1-9.	2.7	1
415	Schizophrenia-associated SAP97 mutations increase glutamatergic synapse strength in the dentate gyrus and impair contextual episodic memory in rats. <i>Nature Communications</i> , 2022, 13, 798.	5.8	8
416	Modern neurosurgical techniques for psychiatric disorders. <i>Progress in Brain Research</i> , 2022, 270, 33-59.	0.9	2
417	Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions. , 2022, , 161-188.		1
418	Transcranial Ultrasound Stimulation Reverses Behavior Changes and the Expression of Calcium-Binding Protein in a Rodent Model of Schizophrenia. <i>Neurotherapeutics</i> , 2022, 19, 649-659.	2.1	3
419	Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2625.	1.8	10
420	Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. <i>NPJ Schizophrenia</i> , 2022, 8, 5.	2.0	48
421	Psychotic disorders in college students: demographic and care considerations. <i>Psychosis</i> , 2023, 15, 229-239.	0.4	4
422	Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. <i>Acta Neuropsychiatrica</i> , 2022, 34, 282-288.	1.0	2
423	Molecular phenotypes associated with antipsychotic drugs in the human caudate nucleus. <i>Molecular Psychiatry</i> , 2022, 27, 2061-2067.	4.1	10
424	A Complex Combination Therapy for a Complex Disease—Neuroimaging Evidence for the Effect of Music Therapy in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2022, 13, 795344.	1.3	2
425	Neuroprotective and Behavioral Benefits of Exogenous Ketone Supplementation-Evoked Ketosis. , 2022, , 423-465.		0
426	The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. <i>Npj Genomic Medicine</i> , 2022, 7, 25.	1.7	8
427	Gray Matter Alterations in Pediatric Schizophrenia and Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis of Voxel-Based Morphometry Studies. <i>Frontiers in Psychiatry</i> , 2022, 13, 785547.	1.3	1
429	Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?. <i>Expert Review of Neurotherapeutics</i> , 2022, , .	1.4	3

#	ARTICLE	IF	CITATIONS
430	Total Brain Volumetric Measures and Schizophrenia Risk: A Two-Sample Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2022, 13, 782476.	1.1	4
431	Temporal Trends in the Incidence and Disability Adjusted Life Years of Schizophrenia in China Over 30 Years. <i>Frontiers in Psychiatry</i> , 2022, 13, 831188.	1.3	11
432	HSPB1 Gene Variants and Schizophrenia: A Case-Control Study in a Polish Population. <i>Disease Markers</i> , 2022, 2022, 1-9.	0.6	2
433	Stability over time of scores on psychiatric rating scales, questionnaires and cognitive tests in healthy controls. <i>BJPsych Open</i> , 2022, 8, e55.	0.3	2
434	We are not ready to abandon the current schizophrenia construct, but should be prepared to do so. <i>Schizophrenia Research</i> , 2022, 242, 30-34.	1.1	9
435	Psychosis, schizophrenia, and states vs. traits. <i>Schizophrenia Research</i> , 2022, 242, 12-14.	1.1	6
436	Relation Between Unconjugated Bilirubin and Peripheral Biomarkers of Inflammation Derived From Complete Blood Counts in Patients With Acute Stage of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2022, 13, 843985.	1.3	4
437	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	2.9	67
438	Ketamine enhances dopamine D1 receptor expression by modulating microRNAs in a ketamine-induced schizophrenia-like mouse model. <i>Neurotoxicology and Teratology</i> , 2022, 91, 107079.	1.2	4
439	Glycolytic and Krebs cycle enzymes activity in rat prefrontal cortex, hippocampus, and striatum after single and repeated NMDA inhibition by MK-801. <i>NeuroToxicology</i> , 2022, 90, 35-47.	1.4	2
440	Altered regional homogeneity and cognitive impairments in first-episode schizophrenia: A resting-state fMRI study. <i>Asian Journal of Psychiatry</i> , 2022, 71, 103055.	0.9	11
441	Endosomal trafficking in schizophrenia. <i>Current Opinion in Neurobiology</i> , 2022, 74, 102539.	2.0	3
442	Frontal lobes dysfunction across clinical clusters of acute schizophrenia. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021, , .	1.0	0
443	Cadence discovery: study protocol for a dose-finding and mechanism of action clinical trial of sodium benzoate in people with treatment-refractory schizophrenia. <i>Trials</i> , 2021, 22, 918.	0.7	2
444	P.0879 Candidate genes of schizophrenia methylation patterns and brain structural correlates. <i>European Neuropsychopharmacology</i> , 2021, 53, S643-S644.	0.3	0
445	BST-1 as a serum protein biomarker involved in neutrophil infiltration in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 537-547.	1.3	4
446	Neuroimaging brain growth charts: A road to mental health. <i>Psychoradiology</i> , 2021, 1, 272-286.	1.0	9
447	Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN). <i>Frontiers in Psychiatry</i> , 2021, 12, 767756.	1.3	2

#	ARTICLE	IF	CITATIONS
448	Novel open reading frames in human accelerated regions and transposable elements reveal new leads to understand schizophrenia and bipolar disorder. <i>Molecular Psychiatry</i> , 2022, 27, 1455-1468.	4.1	11
449	Prospective, observational, single-centre cohort study with an independent control group matched for age and sex aimed at investigating the significance of cholinergic activity in patients with schizophrenia: study protocol of the CLASH-study. <i>BMJ Open</i> , 2021, 11, e050501.	0.8	2
450	Long non-coding RNA-associated competing endogenous RNA axes in the olfactory epithelium in schizophrenia: a bioinformatics analysis. <i>Scientific Reports</i> , 2021, 11, 24497.	1.6	9
451	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. <i>European Psychiatry</i> , 2022, 65, 1-35.	0.1	4
452	The instrumental role of operant paradigms in translational psychiatric research: Insights from a maternal immune activation model of schizophrenia risk. <i>Journal of the Experimental Analysis of Behavior</i> , 2022, 117, 560-575.	0.8	1
453	Understanding the Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 880544.	1.8	39
454	Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 701-708.	1.0	2
455	Comparison of prediction methods for treatment continuation of antipsychotics in children and adolescents with schizophrenia. <i>Evidence-Based Mental Health</i> , 2022, 25, e26-e33.	2.2	1
463	Characteristics of interactive communication between Pepper robot, patients with schizophrenia, and healthy persons. <i>Belitung Nursing Journal</i> , 2022, 8, 176-184.	0.4	2
464	Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, 795866.	1.3	8
465	Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4764.	1.8	14
466	Mammalian D-cysteine: A novel regulator of neural progenitor cell proliferation. <i>BioEssays</i> , 2022, 44, e2200002.	1.2	11
467	Exome sequencing of Japanese schizophrenia multiplex families supports the involvement of calcium ion channels. <i>PLoS ONE</i> , 2022, 17, e0268321.	1.1	0
468	Applying a Fast-Scan Cyclic Voltammetry to Explore Dopamine Dynamics in Animal Models of Neuropsychiatric Disorders. <i>Cells</i> , 2022, 11, 1533.	1.8	10
469	Impact of a Virtual Reality-Based Simulation on Empathy and Attitudes Toward Schizophrenia. <i>Frontiers in Psychology</i> , 2022, 13, .	1.1	6
470	The Interplay between Vitamin D, Exposure of Anticholinergic Antipsychotics and Cognition in Schizophrenia. <i>Biomedicines</i> , 2022, 10, 1096.	1.4	10
471	Influence of positive and negative symptoms on hedonic and eudaemonic well-being in people with schizophrenia: A longitudinal analysis from the EuroSc study. <i>Schizophrenia Research</i> , 2022, 244, 21-28.	1.1	2
472	Changes of immune-related factors in the blood of schizophrenia and bipolar disorder patients receiving monotherapy. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	0

#	ARTICLE	IF	CITATIONS
474	Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 795-806.	1.0	5
475	Targeting NMDA receptors in neuropsychiatric disorders by drug screening on human neurons derived from pluripotent stem cells. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	12
476	Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	8
477	The impact of anorexia nervosa and BMI polygenic risk on childhood growth: A 20-year longitudinal population-based study. <i>American Journal of Human Genetics</i> , 2022, 109, 1242-1254.	2.6	4
478	The causal relationship between sleep traits and the risk of schizophrenia: a two-sample bidirectional Mendelian randomization study. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	8
479	Psychiatric symptoms and mortality in older adults with major psychiatric disorders: results from a multicenter study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 627-638.	1.8	2
480	Intestinal Microbes in Patients With Schizophrenia Undergoing Short-Term Treatment: Core Species Identification Based on Co-Occurrence Networks and Regression Analysis. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
481	BET-ting on histone proteomics in schizophrenia. <i>Trends in Neurosciences</i> , 2022, , .	4.2	1
482	Corticosterone antagonist or TrkB agonist attenuates schizophrenia-like behavior in a mouse model combining Bdnf-e6 deficiency and developmental stress. <i>IScience</i> , 2022, 25, 104609.	1.9	5
483	GSK3 β and mTORC1 Represent 2 Distinct Signaling Markers in Peripheral Blood Mononuclear Cells of Drug-Naïve, First Episode of Psychosis Patients. <i>Schizophrenia Bulletin</i> , 2022, 48, 1136-1144.	2.3	0
484	A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. <i>CNS Drugs</i> , 2022, 36, 659-679.	2.7	38
485	Polygenic scores for schizophrenia and major depression are associated with psychosocial risk factors in children: evidence of gene-environment correlation. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 1140-1152.	3.1	4
486	Herpes simplex virus 1 infection on grey matter and general intelligence in severe mental illness. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	5
487	Free-of-charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications. <i>Basic and Clinical Pharmacology and Toxicology</i> , 0, , .	1.2	2
488	Neurodevelopmental model of schizophrenia revisited: similarity in individual deviation and idiosyncrasy from the normative model of whole-brain white matter tracts and shared brain-cognition covariation with ADHD and ASD. <i>Molecular Psychiatry</i> , 2022, 27, 3262-3271.	4.1	9
489	Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1433-1440.	1.0	5
490	The Antioxidant N-Acetyl-L-Cysteine Restores the Behavioral Deficits in a Neurodevelopmental Model of Schizophrenia Through a Mechanism That Involves Nitric Oxide. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
491	Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. , 2022, 236, 108236.		19

#	ARTICLE	IF	CITATIONS
492	Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study. <i>Schizophrenia Research</i> , 2022, 246, 268-276.	1.1	1
493	Dysregulation of Synaptic Plasticity Markers in Schizophrenia. <i>Indian Journal of Clinical Biochemistry</i> , 2023, 38, 4-12.	0.9	2
494	The role of histone modifications: from neurodevelopment to neurodiseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	63
495	Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1479-1493.	1.0	1
496	Evaluation of Changes in Peripheral Biomarkers Related to Blood Brain Barrier Damage in Patients with Schizophrenia and Their Correlation with Symptoms. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 504-513.	0.9	6
497	Levetiracetam Attenuates Adolescent Stress-induced Behavioral and Electrophysiological Changes Associated With Schizophrenia in Adult Rats. <i>Schizophrenia Bulletin</i> , 2023, 49, 68-77.	2.3	7
498	Using animal models for the studies of schizophrenia and depression: The value of translational models for treatment and prevention. <i>Frontiers in Behavioral Neuroscience</i> , 0, 16, .	1.0	10
499	Potential diagnostic biomarkers for schizophrenia. <i>Medical Review</i> , 2022, 2, 385-416.	0.3	1
500	Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic Approach in the Treatment of Schizophrenia. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, .	0.8	0
503	Exploration of the relationship between hippocampus and immune system in schizophrenia based on immune infiltration analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
504	Low income and schizophrenia risk: A narrative review. <i>Behavioural Brain Research</i> , 2022, 435, 114047.	1.2	5
505	An unsupervised machine learning approach using passive movement data to understand depression and schizophrenia. <i>Journal of Affective Disorders</i> , 2022, 316, 132-139.	2.0	5
506	Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 2003-2019.	1.0	5
507	Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 89-103.	0.8	3
508	What Can We Learn from Animal Models to Study Schizophrenia?. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 15-33.	0.8	0
509	The paradox of family care for patients with schizophrenia: A qualitative study. <i>Journal of Nursing and Midwifery Sciences</i> , 2022, 9, 211.	0.5	1
510	STS-BN: An efficient Bayesian network method for detecting causal SNPs. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
511	Targeting the Renin-Angiotensin System (RAS) for Neuropsychiatric Disorders. <i>Current Neuropharmacology</i> , 2022, 20, .	1.4	3

#	ARTICLE	IF	CITATIONS
512	Interventions to Improve Medication Adherence in People with Schizophrenia: A Systematic Review. Patient Preference and Adherence, 0, Volume 16, 2431-2449.	0.8	6
513	Health care workers'™ perspectives on the challenges and possibilities of music therapy within medication-free treatment services. Nordic Journal of Music Therapy, 0, , 1-19.	0.7	0
514	Genetic regulatory and biological implications of the 10q24.32 schizophrenia risk locus. Brain, 0, , .	3.7	3
515	Reversal of oxidative stress, cytokine toxicity and DNA fragmentation by quercetin in dizocilpine-induced animal model of Schizophrenia. Metabolic Brain Disease, 0, , .	1.4	0
516	Altered dynamic functional connectivity of auditory cortex and medial geniculate nucleus in first-episode, drug-naïve schizophrenia patients with and without auditory verbal hallucinations. Frontiers in Psychiatry, 0, 13, .	1.3	1
517	Pathological oligodendrocyte precursor cells revealed in human schizophrenic brains and trigger schizophrenia-like behaviors and synaptic defects in genetic animal model. Molecular Psychiatry, 2022, 27, 5154-5166.	4.1	10
518	Motion energy analysis during speech tasks in medication-naïve individuals with at-risk mental states for psychosis. , 2022, 8, .		5
519	Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation. BMC Psychiatry, 2022, 22, .	1.1	3
520	Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets. , 2023, 241, 108279.		17
521	Activation of the left medial temporal gyrus and adjacent brain areas during affective theory of mind processing correlates with trait schizotypy in a nonclinical population. Social Cognitive and Affective Neuroscience, 2023, 18, .	1.5	3
522	Microglia involvement in sex-dependent behaviors and schizophrenia occurrence in offspring with maternal dexamethasone exposure. , 2022, 8, .		5
523	New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International Journal of Molecular Sciences, 2022, 23, 10624.	1.8	22
524	Microcrystals of Ketal-Linked Paliperidone Prodrugs for Long-Acting Antipsychotics. Molecular Pharmaceutics, 2022, 19, 3846-3857.	2.3	4
525	Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis. Neuropsychopharmacology, 2022, 47, 2245-2251.	2.8	2
526	Analysis of the association between <sc>MICA</sc> gene polymorphisms and schizophrenia. Journal of Clinical Laboratory Analysis, 0, , .	0.9	1
527	Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders. International Journal of Molecular Sciences, 2022, 23, 11579.	1.8	1
528	Schizophrenia: One Name, Many Different Manifestations. Medical Clinics of North America, 2023, 107, 61-72.	1.1	12
529	Decreased Prosaposin and Progranulin in the Cingulate Cortex Are Associated with Schizophrenia Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 12056.	1.8	1

#	ARTICLE	IF	CITATIONS
530	A five-year follow-up of the verbal memory performance of individuals with bipolar disorder and schizophrenia: evidence of unchanging deficits under treatment. <i>Cognitive Neuropsychiatry</i> , 2023, 28, 19-35.	0.7	2
531	Induced pluripotent stem cell-derived astrocytes from patients with schizophrenia exhibit an inflammatory phenotype that affects vascularization. <i>Molecular Psychiatry</i> , 2023, 28, 871-882.	4.1	4
532	Genetic Analysis of RASD1 as a Candidate Gene for Schizophrenia. <i>Balkan Medical Journal</i> , 2022, 39, 422-428.	0.3	1
533	Synaptic plasticity in Schizophrenia pathophysiology. <i>IBRO Neuroscience Reports</i> , 2022, 13, 478-478.	0.7	3
534	The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia. <i>CNS Spectrums</i> , 2023, 28, 541-560.	0.7	5
535	Analysis of the caudate nucleus transcriptome in individuals with schizophrenia highlights effects of antipsychotics and new risk genes. <i>Nature Neuroscience</i> , 2022, 25, 1559-1568.	7.1	19
536	Cerebral blood flow in schizophrenia: A systematic review and meta-analysis of MRI-based studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2023, 121, 110669.	2.5	7
537	Discovery of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 2-(5-(4-chloro-[1,1'-biphenyl]-4-yl)-4H-1,2,4-triazol-3-yl)ethan-1-amine (LK00764) for the Treatment of Psychotic Disorders. <i>Biomolecules</i> , 2022, 12, 1650.	1.8	2
538	Cannabidiol for people with schizophrenia. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
539	Body mass index and mortality in patients with schizophrenia spectrum disorders: a cohort study in a South London catchment area. <i>Annals of General Psychiatry</i> , 2022, 35, e100819.	1.1	4
540	Factors and their weight in reducing life expectancy in schizophrenia. <i>Schizophrenia Research</i> , 2022, 250, 67-75.	1.1	8
541	Comprehensive bioinformatics analysis and molecular validation of lncRNAs-mediated ceRNAs network in schizophrenia. <i>Life Sciences</i> , 2023, 312, 121205.	2.0	1
542	Catalase and interleukin-6 serum elevation in a prediction of treatment-resistance in male schizophrenia patients. <i>Asian Journal of Psychiatry</i> , 2023, 79, 103400.	0.9	4
543	Sensory gating deficits and childhood trauma in the onset of first-episode schizophrenia. <i>Asian Journal of Psychiatry</i> , 2023, 80, 103385.	0.9	2
544	Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole). <i>Zhurnal Nevrologii i Psikhiatrii Imeni S S Korsakova</i> , 2022, 122, 63.	0.1	0
545	Current progress in understanding schizophrenia using genomics and pluripotent stem cells: A meta-analytical overview. <i>Schizophrenia Research</i> , 2022, .	1.1	8
546	Effect of Virtual Reality on Cognitive Impairment and Clinical Symptoms among Patients with Schizophrenia in the Remission Stage: A Randomized Controlled Trial. <i>Brain Sciences</i> , 2022, 12, 1572.	1.1	1
547	Ultra-high field neuroimaging in psychosis: A narrative review. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2

#	ARTICLE	IF	CITATIONS
548	Antipsychotic- and Anxiolytic-like Properties of a Multimodal Compound JJGW08 in Rodents. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15929.	1.8	3
549	Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. <i>Journal of Molecular Neuroscience</i> , 0, , .	1.1	0
550	Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1279-1290.	1.9	4
551	Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. <i>Journal of Medical Economics</i> , 2023, 26, 70-83.	1.0	10
552	The MAM Model to Study the Role of Dopamine in Schizophrenia. <i>Neuromethods</i> , 2023, , 223-245.	0.2	0
553	High Risk, High Dose?â€”Pharmacotherapeutic Prescription Patterns of Offender and Non-Offender Patients with Schizophrenia Spectrum Disorder. <i>Biomedicines</i> , 2022, 10, 3243.	1.4	3
554	Reviewing the Potential Therapeutic Approaches Targeting the Modulation of Gastrointestinal Microflora in Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16129.	1.8	3
555	Association of daytime napping frequency and schizophrenia: a bidirectional two-sample Mendelian randomization study. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	2
556	Managing Schizophrenia: A Challenge for Physicians. , 2023, , 127-147.		1
557	CCPNet136: automated detection of schizophrenia using carbon chain pattern and iterative TQWT technique with EEG signals. <i>Physiological Measurement</i> , 2023, 44, 035008.	1.2	8
558	The contribution of the 5-hydroxytryptamine receptor 2A gene polymorphisms rs6311 and rs6313 to Schizophrenia in Iran. <i>Molecular Biology Reports</i> , 2023, 50, 2633-2639.	1.0	2
559	Brain Inflammatory Marker Abnormalities in Major Psychiatric Diseases: a Systematic Review of Postmortem Brain Studies. <i>Molecular Neurobiology</i> , 2023, 60, 2116-2134.	1.9	2
560	1D-convolutional neural network approach and feature extraction methods for automatic detection of schizophrenia. <i>Signal, Image and Video Processing</i> , 2023, 17, 2627-2636.	1.7	4
561	Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic. <i>Annals of General Psychiatry</i> , 2023, 22, .	1.2	1
563	Two-year cohort-up study of clozapine prescription in Chinese patients with schizophrenia treated in rural primary care. <i>Asian Journal of Psychiatry</i> , 2023, 81, 103434.	0.9	1
564	Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids. <i>International Journal of Molecular Sciences</i> , 2023, 24, 507.	1.8	2
565	Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia. <i>Psychology Research and Behavior Management</i> , 0, Volume 15, 3915-3929.	1.3	6
566	Prediction of transition to psychosis from an at-risk mental state using structural neuroimaging, genetic, and environmental data. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	3

#	ARTICLE	IF	CITATIONS
585	Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. , 2023, 9, .		2
586	Opportunities and limitations for studying neuropsychiatric disorders using patient-derived induced pluripotent stem cells. <i>Molecular Psychiatry</i> , 2023, 28, 1430-1439.	4.1	5
588	Systematic review and meta-analysis on predictors of prognosis in patients with schizophrenia spectrum disorders: An overview of current evidence and a call for prospective research and open access to datasets. <i>Schizophrenia Research</i> , 2023, 254, 133-142.	1.1	6
589	Benefits of the Neurogenic Potential of Melatonin for Treating Neurological and Neuropsychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4803.	1.8	7
590	Machine learning methods to predict outcomes of pharmacological treatment in psychosis. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	6
591	Inactivation of ERK1/2-CREB Pathway Is Implicated in MK801-induced Cognitive Impairment. <i>Current Medical Science</i> , 2023, 43, 13-21.	0.7	0
592	Current treatment options in early-onset psychosis. , 2023, , 273-298.		0
593	Genetic susceptibility for schizophrenia after adjustment by genetic susceptibility for smoking: implications in identification of risk genes and genetic correlation with related traits. <i>Psychological Medicine</i> , 0, , 1-11.	2.7	0
596	Psychotic Disorders (â€œSchizophreniaâ€). , 2023, , 263-282.		1
597	Machine learning-based predictive models and drug prediction for schizophrenia in multiple programmed cell death patterns. <i>Frontiers in Molecular Neuroscience</i> , 0, 16, .	1.4	2
598	The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders. <i>Advances in Neurobiology</i> , 2023, , 255-285.	1.3	0
601	Children with Early-Onset Psychosis Have Increased Burden of Rare GRIN2A Variants. <i>Genes</i> , 2023, 14, 779.	1.0	2
602	Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 1557-1566.	1.8	14
603	Antipsychotic treatment patterns in refugees and their Swedish-born peers with first-episode non-affective psychosis: findings from the REMAIN study. <i>BJPsych Open</i> , 2023, 9, .	0.3	2
604	A rare case of schizophrenia coexistence with antiphospholipid syndrome, β -thalassemia, and monoclonal gammopathy of undetermined significance. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	1
605	The neural addiction of cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 317-334.	12.8	13
606	Mitochondrial, cell cycle control and neuritogenesis alterations in an iPSC-based neurodevelopmental model for schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 1649-1664.	1.8	3
607	Spatial and Temporal Abnormalities of Spontaneous Fixational Saccades and Their Correlates With Positive and Cognitive Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2024, 50, 78-88.	2.3	2

#	ARTICLE	IF	CITATIONS
615	Ayur-Informatics-Establishing Ligands for Schizophrenic Receptors from Ayurvedic Medicinal Herbs. , 2023, , 81-90.		0
618	Epigenetics and Brain Plasticity: Back to Function. Contemporary Clinical Neuroscience, 2023, , 237-252.	0.3	0
621	Autres applications en psychiatrie. , 2023, , 123-142.		0
625	The Role of Interleukin-6 in the Pathological Mechanisms of Schizophrenia. Neurochemical Journal, 2023, 17, 19-24.	0.2	0
632	Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 1543-1556.	1.8	10
637	Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options. CNS Drugs, 2023, 37, 499-512.	2.7	2
640	The molecular pathology of neurodegenerative and psychiatric disorders. , 2023, , 3-43.		4
641	The Impact of Schizophrenia Misdiagnosis Rates on Machine Learning Models Performance. Lecture Notes in Networks and Systems, 2023, , 3-13.	0.5	0
688	24S-Hydroxycholesterol in Neuropsychiatric Diseases: Schizophrenia, Autism Spectrum Disorder, and Bipolar Disorder. Advances in Experimental Medicine and Biology, 2024, , 293-304.	0.8	0
701	Deep Learning Models for Diagnosis of Schizophrenia Using EEG Signals: Emerging Trends, Challenges, and Prospects. Archives of Computational Methods in Engineering, 0, , .	6.0	1
718	Microbiota in neurodevelopmental disorders. , 2024, , 127-145.		0